Clinical Trial Update: An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares two doses of MVA-nef to MVA-BN in HIV-1 infected patients, assessing immunogenicity and safety. The report provides immunogeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MVA-BN (Modified vaccinia Ankara Bavarian Nordic)
• MVA-nef (Modified Vaccinia Ankara vector expressing HIV-1 nef gene)

Snippet

Sponsor: Bavarian Nordic | Conditions: HIV Infection | Phase 2 | Status: COMPLETED